Kellogg's new plant-based Chick’n Tenders which is part of its MorningStar Farms brand's Incogmeato line will hit US shelves this month.
The Incogmeato Chik’n Tenders will be available in original and sweet BBQ flavors.
The company claims its plant-based Chick’n Tenders offer a “just-like-meat” tear.
According to MorningStar Farms, it utilizes plant-based tear technology to create fibers that replicate chicken texture.
Both Chick’n Tender flavors are made with non-GMO soy and contain no artificial flavorings.
Kellogg claims that its vegan tenders contain more grams of protein per serving and 27 percent less fat than real chicken.
The Incogmeato Chick’n Tenders will be sold nationwide such as select Walmart, Meijer, and Kroger stores. It will also be available to food service operators.


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Washington Post Publisher Will Lewis Steps Down After Layoffs
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



